Biblio

Author Title Type [ Year(Asc)]
Filters: Author is Wynn, Robert  [Clear All Filters]
2024
John TD, Maron G, Abraham A, Bertaina A, Bhoopalan SVelan, Bidgoli A, Bonfim C, Coleman Z, Dezern A, Li J, et al. Strategic infection prevention after genetically modified hematopoietic stem cell therapies: recommendations from the International Society for Cell & Gene Therapy Stem Cell Engineering Committee. Cytotherapy. 2024.
2023
Lum SHan, James B, Ottaviano G, Ewins A-M, Patrick K, Ali S, Carpenter B, Silva J, Tewari S, Furness C, et al. Alemtuzumab, dual GVHD prophylaxis, and lower CD3+ T cell doses equalize rates of acute and chronic GVHD among pediatric patients receiving allogeneic HSCT with matched unrelated donor PBSC or bone marrow grafts. Transplant Cell Ther. 2023.
Cseh A, Galimard J-E, De La Fuente J, Isgrò A, Zecca M, Garwer B, Biffi A, Aljurf M, Sundin M, Belendez C, et al. Busulfan-fludarabine- or treosulfan-fludarabine-based conditioning before allogeneic HSCT from matched sibling donors in paediatric patients with sickle cell disease: A study on behalf of the EBMT Paediatric Diseases and Inborn Errors Working Parties. Br J Haematol. 2023.
Garcia-Rosa M, Abraham A, Bertaina A, Bhoopalan SVelan, Bonfim C, Cohen S, Dezern A, Louis C, Oved J, Pavel-Dinu M, et al. International society for cell & gene therapy stem cell engineering committee: Cellular therapies for the treatment of graft-versus-host-disease after hematopoietic stem cell transplant. Cytotherapy. 2023.
Klein OR, Bonfim C, Abraham A, Ruggeri A, Purtill D, Cohen S, Wynn R, Russell A, Sharma A, Ciccocioppo R, et al. Transplant for non-malignant disorders: an International Society for Cell & Gene Therapy Stem Cell Engineering Committee report on the role of alternative donors, stem cell sources and graft engineering. Cytotherapy. 2023.
Horgan C, Mullanfiroze K, Rauthan A, Patrick K, Butt NAkram, Mirci-Danicar O, O'Connor O, Furness CLouise, Deshpande A, Lawson S, et al. T-replete cord transplants give superior outcomes in high risk and relapsed/refractory paediatric myeloid malignancy. Blood Adv. 2023.
2022
Albert MH, Sirait T, Eikema D-J, Bakunina K, Wehr C, Suarez F, Fox MLaura, Mahlaoui N, Gennery AR, Lankester AC, et al. Hematopoietic stem cell transplantation for adolescents and adults with inborn errors of immunity, an EBMT IEWP study. Blood. 2022.
2021
Gentner B, Tucci F, Galimberti S, Fumagalli F, De Pellegrin M, Silvani P, Camesasca C, Pontesilli S, Darin S, Ciotti F, et al. Hematopoietic Stem- and Progenitor-Cell Gene Therapy for Hurler Syndrome. N Engl J Med. 2021;385(21):1929-1940.
Dimitrova D, Nademi Z, Maccari MElena, Ehl S, Uzel G, Tomoda T, Okano T, Imai K, Carpenter B, Ip W, et al. International retrospective study of allogeneic hematopoietic cell transplantation for activated PI3K-delta syndrome. J Allergy Clin Immunol. 2021.
2020
Cesaro S, Pillon M, Sauer M, Smiers F, Faraci M, de Heredia CDíaz, Wynn R, Greil J, Locatelli F, Veys P, et al. Long-term outcome after allogeneic hematopoietic stem cell transplantation for Shwachman-Diamond syndrome: a retrospective analysis and a review of the literature by the Severe Aplastic Anemia Working Party of the European Society for Blood and Marrow Tra. Bone Marrow Transplant. 2020.
Lum SHan, Orchard PJ, Lund TC, Miller WP, Boelens JJan, Wynn R. Outcome after a cord blood transplantation using busulfan pharmacokinetic targeted myeloablative conditioning for Hurler syndrome. Biol Blood Marrow Transplant. 2020.
2019
Taylor M, Khan S, Stapleton M, Wang J, Chen J, Wynn R, Yabe H, Chinen Y, Boelens JJan, Mason RW, et al. Hematopoietic stem cell transplantation for mucopolysaccharidoses; past, present, and future. Biol Blood Marrow Transplant. 2019.
2016
Lum SHan, Bonney D, Cheesman E, Wrignt NB, Hughes S, Wynn R. Successful Curative Therapy With Rituximab and Allogeneic Haematopoietic Stem Cell Transplantation for MALT Lymphoma Associated With STK4-Mutated CD4+ Lymphocytopenia. Pediatr Blood Cancer. 2016.